1-chloro-5-phenoxypentane | 71933-92-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-chloro-5-phenoxypentane
• 英文别名: (5-chloro-pentyl)-phenyl ether；(5-Chlor-pentyl)-phenyl-aether；(ε-Chlor-amyl)-phenyl-aether；5-phenoxypentyl chloride；Chlorpentylphenylether；Benzene, [(5-chloropentyl)oxy]-；5-chloropentoxybenzene
• CAS: 71933-92-1
• 化学式: C₁₁H₁₅ClO
• 分子量: 198.692
• InChiKey: SXFFGDCBQRSFIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-chloro-5-phenoxypentane 在 乙醇 、 sodium iodide 作用下， 生成 (5-碘-戊基)-苯基醚
  参考文献：
  名称：

  v. Braun; Steindorff, Chemische Berichte, 1905, vol. 38, p. 962

  摘要：

  DOI：
• 作为产物：
  描述：

  1,5-二氯戊烷 、 苯酚 在 sodium hydroxide 、 四丁基硫酸氢铵 作用下， 反应 16.0h， 以94%的产率得到1-chloro-5-phenoxypentane
  参考文献：
  名称：

  Homologs of Idoxifene:  Variation of Estrogen Receptor Binding and Calmodulin Antagonism with Chain Length

  摘要：

  A series of homologs of idoxifene [1a, (E)-1-[4-(N-pyrrolidinoethoxy)phenyl]-1-(4-iodophenyl)-2-phenyl-1-butene] and selected homologs of 4-iodotamoxifen [2a, (E)-1-[4-[N-dimethylamino)-ethoxy]phenyl]-1-(4-iodophenyl)-2-phenyl-1-butene] with the side chain (CH2)(n) varying in length from n = 3 (1b, 2b) to n = 10 (1i, 2i) have been synthesized and tested for antagonism of the calmodulin-dependent activity of cAMP phosphodiesterase and for binding affinity to rat uterine estrogen receptor. Compared with 1a (IC50 = 1.5 mu M), the homologs showed a progressive increase in calmodulin antagonism with a maximum inhibition at n = 7-9 (1f-h) (IC50 = 0.2 mu M), declining at n = 10 (1i) to IC50 = 1.6 mu M. In the pyrrolidino series, estrogen receptor binding affinity peaked at n = 3 (1b, RBA = 23; estradiol = 100), declining by n = 10 (1i) to RBA = 0.4, but the homolog n = 8 (1g, RBA = 3.5) was still comparable to tamoxifen (RBA = 3.9). A similar pattern of activity was seen for the dimethylamino counterparts. These compounds represent a new class of antiestrogens with potent calmodulin antagonism.

  DOI：

  10.1021/jm9505472

文献信息

• Benzoic acid compounds and use thereof as medicaments
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：US05864039A1

  公开（公告）日：1999-01-26

  Benzoic acid compounds of the formula ##STR1## wherein each symbol is as defined in the specification, optical isomers thereof and pharmaceutically acceptable salts thereof; pharmaceutical composition comprising this compound and pharmaceutically acceptable additive; and serotonin 4 receptor agonists, gastrointestinal prokinetic agents and therapeutic agents for various gastrointestinal diseases, which comprise this compound as active ingredient. The compounds of the present invention have high and selective affinity for serotonin 4 receptor, and show agonistic effects thereon. Accordingly, they are useful medications for the prophylaxis and treatment of various gastrointestinal diseases, central nervous disorders, cardiac function disorders, urinary diseases, and the like, as well as useful anti-nociceptors for analgesic use which increase threshold of pain.

  苯甲酸化合物的化学式为##STR1##，其中每个符号如规范中定义，其光学异构体及其药用可接受盐；包括该化合物和药用可接受添加剂的药物组合物；以及将该化合物作为活性成分的5-羟色胺4受体激动剂、胃肠促动力剂和用于各种胃肠疾病的治疗剂。本发明的化合物具有对5-羟色胺4受体的高度和选择性亲和力，并显示出激动效应。因此，它们可用于预防和治疗各种胃肠疾病、中枢神经障碍、心脏功能障碍、泌尿系统疾病等，同时还可用作提高疼痛阈值的镇痛用途的有用抗痛觉剂。
• A novel photoinduced reduction system of low-valent samarium species: reduction of organic halides and chalcogenides, and its application to carbonylation with carbon monoxide
  作者：Yukihito Sumino、Nami Harato、Yuri Tomisaka、Akiya Ogawa

  DOI：10.1016/j.tet.2003.08.070

  日期：2003.12

  irradiation is found to enhance the reducing ability of samarium diiodide (SmI2) dramatically. Organic halides (RCl, RBr, RI) and chalcogenides (RSPh, RSePh, RTePh) are smoothly reduced to the corresponding hydrocarbons by using this SmI2–hv system. The photoactivation can be also applied to ytterbium diiodide (YbI2) successfully. When the reduction of alkyl chlorides (RCl) by using the SmI2–hv system is conducted

  发现可见光照射可显着增强二碘化sa（SmI 2）的还原能力。通过使用此SmI 2 - hv系统，有机卤化物（RCl，RBr，RI）和硫族化物（RSPh，RSePh，RTePh）可以平滑地还原为相应的烃。光活化也可以成功地应用于二碘化（（YbI 2）。当在一氧化碳的压力下使用SmI 2 - hv系统还原烷基氯化物（RCl）时，会获得不对称的酮（RC（O）CH 2 R）作为羰基化产物。机械途径可能涉及酰基sa物种（RC（O）SmI 2），然后进行二聚化，然后用SmI 2还原，得到不对称的酮。
• BENZOIC ACID COMPOUNDS AND MEDICINAL USE THEREOF
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0873990A1

  公开（公告）日：1998-10-28

  A benzoic acid compound of the formula wherein each symbol is as defined in the specification, an optical isomer thereof and a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising this compound and a pharmaceutically acceptable additive, a serotonin 4 receptor agonist comprising this compound as an active ingredient, a gastrointestinal prokinetic agent and a therapeutic agent for gastrointestinal diseases. The compound of the present invention shows selective and high affinity for serotonin 4 receptors, activates same, is useful as a pharmaceutical agent for the prophylaxis and treatment of gastrointestinal diseases (e.g., reflux esophagitis; gastroesophageal reflux such as that accompanying cystic fibrosis; Barrett syndrome; intestinal pseudoileus; acute or chronic gastritis; gastric or duodenal ulcer; Crohn's disease; non-ulcer dyspepsia; ulcerative colitis; postgastrectomy syndrome; postoperative digestive function failure; delayed gastric emptying caused by gastric neurosis, gastroptosis, diabetes, and the like; gastrointestinal disorders such as indigestion, meteorism, abdominal indefinite complaint, and the like; constipation such as atonic constipation, chronic constipation, and that caused by spinal cord injury, pelvic diaphragm failure and the like; and irritable bowel syndrome), central nervous disorders (e.g., schizophrenia, depression, anxiety, disturbance of memory and dementia), cardiac function disorders (e.g., cardiac failure and myocardial ischemia), urinary diseases (e.g., dysuria caused by urinary obstruction, ureterolith, prostatomegaly, spinal cord injury, pelvic diaphragm failure, etc.), and shows superior absorption.

  式中的苯甲酸化合物 其中各符号如说明书中所定义，其光学异构体及其药学上可接受的盐。由该化合物和药学上可接受的添加剂组成的药物组合物、以该化合物为活性成分的血清素 4 受体激动剂、胃肠促动力药和胃肠疾病治疗剂。 本发明的化合物对 5-羟色胺 4 受体具有选择性和高亲和力，能激活 5-羟色胺 4 受体，可用作预防和治疗胃肠道疾病（如反流性食管炎；反流性食管炎；反流性食管炎；反流性食管炎；反流性食管炎；反流性食管炎；反流性食管炎）的药物、反流性食管炎；胃食管反流，如伴随囊性纤维化的胃食管反流；巴雷特综合征；肠道假膜；急性或慢性胃炎；胃或十二指肠溃疡；克罗恩病；非溃疡性消化不良；溃疡性结肠炎；胃切除术后综合征；术后消化功能衰竭；胃神经官能症、胃下垂、糖尿病等引起的胃排空延迟；消化不良、陨石症、腹部不适等胃肠道疾病；失张性便秘、慢性便秘、脊髓损伤引起的便秘、骨盆膈肌功能衰竭等便秘；肠易激综合征）、中枢神经紊乱（如溃疡性结肠炎g.,精神分裂症、抑郁症、焦虑症、记忆障碍和痴呆症）、心脏功能紊乱（如心力衰竭和心肌缺血）、泌尿系统疾病（如尿路梗阻、输尿管结石、前列腺肥大、脊髓损伤、盆腔膈肌衰竭等引起的排尿困难），并显示出良好的吸收性。
• METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS
  申请人：SUMITOMO CHEMICAL COMPANY LIMITED

  公开号：EP0937703A1

  公开（公告）日：1999-08-25

  The present invention is directed to a method for purifying pyruvic acid compounds, which method comprises reacting a pyruvic acid compound of general formula (I): wherein R1 is an optionally substituted lower alkyl group, a lower alkenyl group, a lower alkynyl group, a cycloalkyl group, an aryl group, or a heterocyclic group, and R2 is a lower alkyl group, with a bisulfite of general formula (II):         MHSO3     (II) wherein M is NH4 or an alkali metal, to give a bisulfite adduct of the pyruvic acid compound and then decomposing the adduct with an acid. According to the present invention, pyruvic acid compounds can be purified by simple and easy procedures without using purification techniques such as distillation or column chromatography, and the above method is advantageous as a process for the production on an industrial scale.

  本发明涉及一种纯化丙酮酸化合物的方法，该方法包括使通式(I)的丙酮酸化合物反应： 其中 R1 是任选取代的低级烷基、低级烯基、低级炔基、环烷基、芳基或杂环基，R2 是低级烷基，与通式（II）的亚硫酸氢盐反应： MHSO3 (II) 其中 M 为 NH4 或碱金属，以得到丙酮酸化合物的亚硫酸氢盐加合物，然后用酸分解该加合物。根据本发明，丙酮酸化合物可以通过简单易行的程序进行纯化，而无需使用蒸馏或柱层析等纯化技术，上述方法作为一种工业规模的生产工艺是非常有利的。
• METHOD OF PRODUCING (METH)ACRYLOYL-TERMINATED POLYISOBUTYLENE POLYMER
  申请人：Kaneka Corporation

  公开号：EP3388454A1

  公开（公告）日：2018-10-17

  The object of the present invention is to provide a method for producing a (meth)acryloyl-terminated polyisobutylene polymer in which the auxiliary material used in the manufacture is easily removed, the burden of purification step and waste amount are decreased, and the transparency of the polymer is excellent. The method for producing the (meth)acryloyl-terminated polyisobutylene polymer contains a step 1 of polymerizing an isobutylene monomer under the presence of a Lewis acid catalyst to prepare a halogen-terminated polyisobutylene polymer (B), a step 2 of reacting the halogen-terminated polyisobutylene polymer (B) with a compound (C) having a halogen group and a phenoxy group under the presence a Lewis acid catalyst to prepare a halogenated phenoxyalkyl-terminated polyisobutylene polymer (D), and a step 3 of reacting the halogenated phenoxyalkyl-terminated polyisobutylene polymer (D) with an acrylic acid compound (E) to prepare the (meth)acryloyl-terminated polyisobutylene polymer (A).

  本发明的目的是提供一种生产(甲基)丙烯酰基封端的聚异丁烯聚合物的方法，该方法易于去除生产中使用的辅助材料，减少了纯化步骤的负担和废物量，并且聚合物的透明度极佳。(甲基)丙烯酰基封端聚异丁烯聚合物的生产方法包括步骤 1：在路易斯酸催化剂存在下聚合异丁烯单体，制备卤素封端聚异丁烯聚合物 (B)、步骤 2：在路易斯酸催化剂存在下，将卤素封端聚异丁烯聚合物（B）与具有卤素基和苯氧基的化合物（C）反应，制备卤代苯氧基烷基封端聚异丁烯聚合物（D），步骤 3：将卤代苯氧基烷基封端聚异丁烯聚合物（D）与丙烯酸化合物（E）反应，制备（甲基）丙烯酰基封端聚异丁烯聚合物（A）。